2. Immunology/Inflammation NF-κB Apoptosis
  3. Toll-like Receptor (TLR) NF-κB TNF Receptor Interleukin Related
  4. SMU-Z1

SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8+T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research.

For research use only. We do not sell to patients.

SMU-Z1

SMU-Z1 Chemical Structure

CAS No. : 2410782-66-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SMU-Z1 Related Antibodies

Top Publications Citing Use of Products

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8+T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research[1].

In Vitro

SMU-Z1 specifically activates the TLR1/2 heterodimer in HEK-Blue hTLR2 cells, with an EC50 of 4.88 × 10-9 M[1].
SMU-Z1 (0-10 μM; 24 h) dose-dependently stabilizes the TLR2 protein in HEK-Blue hTLR2 cells[1].
SMU-Z1 (0-5 μM; 24 h) dose-dependently activates the NF-κB signaling pathway in stably transfected human macrophage U937 cells[1].
SMU-Z1 (0-10 μM; 24 h) dose-dependently stimulates the production of TNF-α and IL-1β in Raw 264.7 mouse macrophages[1].
SMU-Z1 (0-10 μM; 24 h) dose-dependently stimulates the production of TNF-α and IL-1β in human peripheral blood mononuclear cells (PBMC)[1].
SMU-Z1 (0-1000 nM; 24 h) stimulates Raw 264.7 mouse macrophages to produce NO[1].
SMU-Z1 (0-10 μM; 24 h) upregulates the mRNA expression of IL-6 and IL-8 in PBMC[1].
SMU-Z1 (0-5 μM; 24-72 h) promotes the proliferation of primary splenocytes from C57Bl/6 mice[1].
SMU-Z1 (0-1000 nM; 48-72 h) dose-dependently activates the proliferation of naive T cells isolated from C57Bl/6 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SMU-Z1 Related Antibodies

Western Blot Analysis[1]

Cell Line: HEK-Blue hTLR2 cells
Concentration: 0, 0.01, 0.1, 1, 10 μM
Incubation Time: 24 h
Result: Increased TLR2 protein stability in a dose-dependent manner, with higher TLR2 protein levels observed as concentrations increased from 0.01 to 10 μM.

ELISA Assay[1]

Cell Line: Raw 264.7 mouse leukemic monocyte macrophage cells
Concentration: 0.0007, 0.002, 0.006, 0.018, 0.036, 0.12, 0.4, 1 μM (TNF-α); 0.0015, 0.0043, 0.0133, 0.04, 0.12, 0.4, 1.2, 3.6, 10 μM (IL-1β)
Incubation Time: 24 h
Result: Stimulated dose-dependent production of TNF-α and IL-1β.
Increased TNF-α levels from ~2000 pg/mL at 0.006 μM to ~4000 pg/mL at 1 μM.
Increased IL-1β levels from ~50 pg/mL at 0.0043 μM to ~550 pg/mL at 10 μM.

Cell Proliferation Assay[1]

Cell Line: C57Bl/6 mouse primary splenocytes
Concentration: 0, 0.1, 0.5, 1, 5 μM
Incubation Time: 0, 24, 48, 72 h
Result: Dependently promoted proliferation of C57Bl/6 mouse primary splenocytes, with a 3-5-fold increase observed at 5 μM after 48 h of incubation.
In Vivo

SMU-Z1 (0.3 mg; intraperitoneal injection; once every 5 days; D7-D32) reduces tumor volume in leukemia xenograft mouse models, while increasing the frequencies of CD8+ T cells, NK cells and DC cells infiltrating the spleen and tumors[1].
SMU-Z1 (0.1 mg; intraperitoneal injection; single dose) increases the frequencies of splenic CD8+ T cells and CD3+CD8+TLR2+ T cells in normal mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (8-week-old male, 17-19 g, subcutaneous inoculation of 5 × 105 syngeneic murine FBL3 leukemia cancer cells)[1]
Dosage: 0.3 mg
Administration: i.p.; once every 5 days
Result: Reduced mean tumor volume to 386 mm3 on day 35 (vs. 2370 mm3 in PBS controls).
Induced complete tumor disappearance in 3 out of 7 treated mice after three administrations.
Increased splenic CD3+ T cells to 25.7% (vs. 11.6% in controls).
Increased splenic CD8+ T cells to 19.4% (vs. 10.6% in controls).
Increased splenic CD8/CD4 ratio to 0.28 (vs. 0.13 in controls).
Increased splenic NK cells to 10.5% (vs. 4.64% in controls).
Increased splenic DC cells to 3.87% (vs. 1.54% in controls).
Increased tumor tissue CD3+ T cells to 37.0%.
Increased tumor tissue CD8+CD3+ T cells to 28.1%.
Increased tumor tissue NK cells to 3.66%.
Increased tumor tissue DC cells to 4.12%.
Caused no significant change in mouse body weight relative to controls.
Animal Model: C57BL/6 (8-10-week-old male)[1]
Dosage: 0.1 mg
Administration: i.p.; single administration
Result: Increased splenic CD8+ T cells to 27.4% after 7 days (vs. 17.1% in PBS controls).
Increased splenic CD8+ T cells to 21.3% after 5 days (vs. 16.7% in PBS controls).
Increased splenic CD3+CD8+TLR2+ T cells to 6.3% after 5 days (vs. 2.6% in PBS controls).
Increased splenic CD3+CD8+TLR2+ T cells to 6.7% after 7 days (vs. 2.6% in PBS controls).
Reduced splenic CD4+ T cells to 55.6% (vs. 69.5% in PBS controls).
Increased the splenic CD8/CD4 ratio.
Caused no significant change in splenic CD19+ B cell frequencies.
Molecular Weight

378.31

Formula

C17H13F3N4O3
CAS No.
SMILES

CNC(C(N1C=NC(C2=C(O)C=C(C(F)(F)F)C=C2)=C1)=C3)=CC=C3[N+]([O-])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SMU-Z1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SMU-Z12410782-66-8Toll-like Receptor (TLR)NF-κBTNF ReceptorInterleukin RelatedNuclear factor-κBNuclear factor-kappaBTumor Necrosis Factor ReceptorTNFRILIL-1βIL-6U937 human macrophage cellsTNF-αHEK-Blue hTLR2 cellsNK cellsRaw 264.7 mouse macrophage cellsTLR1/2 heterodimerNF-κB pathwayCD8+ T cellsleukemiaC57BL/6 miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SMU-Z1
Cat. No.:
HY-182644
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.